Articles by Melissa Badamo
At a median follow-up of 28.6 months, the ORR was 100% and the CR+ CRi rate was 45%.
There were no differences in OS among patients with NPM1-mutated myeloid neoplasms with varying bone marrow blasts.
Azacitidine plus quizartinib achieved a high ORR and a promising safety profile in patients with FLT3-Mutated MDS.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
New therapies, such as TP-3654, are currently being explored in combination studies.
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
The Beat AML trial has provided practice-changing insights and allows investigators to assess the potential of novel agents.
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
Venetoclax plus obinutuzumab was associated with longer PFS compared with chemoimmunotherapy.
There were no significant differences in OS or PFS between allogeneic HSCT and autologous HSCT.
Three of four patients with myelofibrosis had objective responses at one year, and no dose-limiting toxicities were observed.
No significant differences in HSCT were observed, suggesting haploidentical HSCT as an acceptable treatment approach.
Odronextamab showed durable response rates and an acceptable safety profile in the phase I ELM-1 and phase II ELM-2 trials.
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Julie Braish, MBBCh, discusses her study on JAK2 allele burden in myelofibrosis presented at ASCO 2024.
The approval was based on results from the EPCORE® NHL-1 trial, in which epcoritamab achieved an ORR of 82%.
Achieving complete cytogenetic response results in the best overall survival in patients with MDS with abnormal cytogenetics.
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.